Areteia Therapeutics Announces Start of Phase III Clinical Trials of Oral Dexpramipexole in Eosinophilic Asthma
Areteia Therapeutics announced today that the first patients have been dosed in both the EXHALE-2 and EXHALE-4 trials as part of its overall Phase III clinical program investigating the efficacy and safety of oral dexpramipexole in severe eosinophilic asthma. A total of three clinical studies are planned as part of the overall Phase III development program.
EXHALE-2 is a 52 week, randomized, double-blind, placebo-controlled global study (n=1,395 participants) which will evaluate the efficacy of dexpramipexole in reducing severe asthma exacerbations as compared to placebo as its primary endpoint. An additional global phase 3 study (titled EXHALE-3) is planned to similarly evaluate reduction in exacerbations as compared to placebo as its primary endpoint.
EXHALE-4 is a 24 week, randomized, double-blind, placebo-controlled global study (n=750 participants) which will evaluate change in lung function compared to placebo as its primary endpoint. Lung function will be measured by change in forced expiratory volume (FEV1).
“We are excited about dexpramipexole as a potential novel oral therapy for the millions of patients worldwide who are impacted by eosinophilic asthma. If approved, dexpramipexole would represent the first oral drug for these patients,” said Jorge Bartolome, Chief Executive Officer of Areteia Therapeutics.
Dexpramipexole inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. Most recently in a Phase II study (EXHALE-1) in patients with moderate-to-severe eosinophilic asthma, treatment with dexpramipexole resulted in a significant, dose-dependent reduction in blood absolute eosinophil count at all doses tested (dexpramipexole doses of 37.5 mg, 75 mg, or 150 mg twice daily) compared to placebo. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation.
About Areteia Therapeutics
Areteia Therapeutics (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia’s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase 3 clinical trials, secure commercial supply, and pursue potential next-generation medicines. Areteia is conducting late-stage development including Phase 3 clinical trials of dexpramipexole in partnership with Population Health Partners’ development unit, Validae Health.
About Eosinophilic Asthma
Asthma disrupts the lives of more than a quarter of a billion people worldwide. More than half of asthma patients have eosinophilic asthma, which is driven by an oversupply of eosinophils, a type of white blood cell, in blood and tissue. By inhibiting the maturation of eosinophils, oral dexpramipexole acts in a way similar to injectable anti-IL-5 biologic therapies. The asthma biologic market is experiencing growth of 10% per year and is valued at around $8 billion, with IL-5 biologic therapies representing approximately $3 billion of that figure. If approved as a first-to-market oral drug, dexpramipexole could provide a compelling alternative to injectable biologics, and could potentially be used earlier in the asthma treatment paradigm to prevent progression of disease.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005048/en/
Tamsin Berry Tamsin.Berry@areteiatx.com
Mark Kreston Mark.Kreston@areteiatx.com
About Business Wire
24 Martin Lane
EC4R 0DR London
+44 20 7626 1982http://www.businesswire.co.uk
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Huawei Releases 2022 Annual Report: Steady Operations, Sustainable Survival and Development31.3.2023 11:59:00 CEST | Press release
Huawei released its 2022 Annual Report today. The company reports steady operations throughout 2022, having generated CNY642.3 billion in revenue and CNY35.6 billion in net profits. Huawei continues to strengthen investment in R&D, with an annual expenditure of CNY161.5 billion in 2022, representing 25.1% of the company's annual revenue and bringing its total R&D expenditure over the past 10 years to more than CNY977.3 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230331005166/en/ (Photo: Huawei) "In 2022, a challenging external environment and non-market factors continued to take a toll on Huawei's operations", said Eric Xu, Huawei's Rotating Chairman, at the company's annual report press conference. "In the midst of this storm, we kept racing ahead, doing everything in our power to maintain business continuity and serve our customers. We also went to great lengths to grow the harvest – generating a steady stream
L&T Technology Services and Ansys set up CoE for Digital Twin31.3.2023 09:30:00 CEST | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, and Ansys, a global leader and pioneer of Multiphysics engineering simulation software have signed an MOU to establish the LTTS-Ansys Center of Excellence (CoE) for Digital Twin. The center will support LTTS in demonstrating industry use cases, develop future facing solutions, and enable its customers to optimize design, manufacturing, and supply chain processes. Ansys' Twin Builder solution will allow LTTS to further expand its market share in digital twin areas. The digital twin market is valued at $6.5 billion and is expected to reach $125.7 billion by 2030, growing at a CAGR of 39.48%. The CoE will help LTTS showcase digital twin proofs of concept to its customers and speed up their adoption. The collaboration will enable LTTS to meet the growing demand for digital twin solutions and provide access to emerging talent in the technology market. The joint efforts of Ansys
Horizon Quantum Computing Raises USD 18.1 million Series A to Advance Quantum Software Development31.3.2023 09:30:00 CEST | Press release
Horizon Quantum Computing,a Singapore-based company building software development tools to unlock the potential of quantum computing hardware, announced today that it has raised USD 18.1 million Series A investment from Sequoia Capital India, Tencent, SGInnovate, Pappas Capital and Expeditions Fund. The investment round will boost the growth of the company, allowing it to strengthen its science and engineering teams to accelerate product development, establish its new engineering centre in Europe and bring Horizon’s unique technology to the market. Horizon Quantum Computing’s total funding now stands at approximately USD 21.3 million. “Quantum computing has the potential to completely change how we think about computing,” says Horizon’s CEO Dr Joe Fitzsimons. “While getting to large scale quantum computing is a daunting challenge, it is undeniable that progress towards that goal is being made. At Horizon, we focus on unlocking the power of future quantum computers, and have made signif
Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse ® G ApoE4 and Lumipulse ® G Pan-ApoE assays for Research Use Only31.3.2023 08:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays for the fully automated LUMIPULSE® G Systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of the E4 isoform of the apolipoprotein E (ApoE4), specifically, and for all isoforms of the same protein (Pan-ApoE), respectively, in human plasma within just 35 minutes. The two new automated blood-based biomarker assays are available for Research Use Only. “One year after the release of the first blood-based biomarkers for Alzheimer’s disease on our robust LUMIPULSE G platform, Fujirebio adds another two markers to its steadily growing portfolio,” said Christiaan De Wilde, CEO of Fujirebio Europe NV and Global Head Neuro Business. “These new assays will further support biomarker research in the field of neurodegenerative diseases, an important mission for Fujirebio.” The Lumipulse G ApoE4
Hai Robotics Wins Innovation Award for Existing Product at Promat 202331.3.2023 04:26:00 CEST | Press release
Hai Robotics, a leading provider of intelligent automated warehousing solutions, has won the MHI Innovation Award for Best Innovation of an Existing Product for their A42T Autonomous Case-handling Robot (ACR). This prestigious award was announced at ProMat 2023, held in Chicago, on Wednesday, March 22nd. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230327005769/en/ The MHI Innovation Award recognizes Hai Robotics for their groundbreaking work in developing advanced equipment for automated storage and retrieval solutions (ASRS) and recognizes the company's commitment to advancing their customer’s success with innovative and cutting-edge technology. The A42T ACR is the first goods-to-person equipment that extends upward allowing facilities to store items up to 10m (32+ feet) high, while remaining independent of any storage medium. It is highly intelligent, able to handle most totes or container sizes and types, even cardboar